FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
Section 16 Form 4 or Form 5		• • • • • • • • • • • • • • • • • • • •

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Quan Joanne (Last) (First) (Middle) 350 CAMBRIDGE AVE, SUITE 350					Issuer Name and Ticker or Trading Symbol Eiger BioPharmaceuticals, Inc. [EIGR] Date of Earliest Transaction (Month/Day/Year) 03/14/2018								5. Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title below) below) Chief Medical Officer					
(Street) PALO ALTO CA 94306 (City) (State) (Zip)				_	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				ansaction	tion 2A. Deemed Execution Date,			3. Transacti Code (Ins 8)	ransaction Disposed Of (D) (Instr. 3 5)		ed (A) or tr. 3, 4 and	5. Amou Securitie Benefici	nt of es form (D) of (I) (In tion(s)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
			Table II - Deri (e.g					uired, Dis , options,			or Ben			anu 4)				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) ve	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Instr.				6. Date Exercisabl Expiration Date (Month/Day/Year)		of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	· V (A)		(D)	Date Exercisable	Expirat Date	tion	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$9.5	03/14/2018		A		60,000		(1)	03/13/2	2028	Common Stock	60,000	\$0.00	60,00	0	D		

Explanation of Responses:

1. The option vests in equal monthly installments over 48 months measured from March 14, 2018 subject to Reporting Person's continuous service status as of each such date.

Remarks:

/s/ James H. Welch, Attorneyin-Fact 03/16/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.